Project description and overview:

This project is the first phase of re-shoring manufacturing capability for Primers from sub-contract manufacturers, who are based in the United States, and most importantly, being able protect Microbio’s core IP for Primer manufacturing from now on. Upon completion of component manufacture, Microbio will be in a position to conduct scale manufacture of its Primers in Brisbane.

InfectID is a unique PCR platform technology that provides rapid, highly sensitive bacterial, fungal and viral pathogen identification in clinical samples for both defence and civilian personnel. InfectID provides a significant reduction in test setup and running costs compared to fluorescent probes.

At the core of the unique design, the InfectID tests are aimed at highly discriminatory genetic targets. These targets have been applied to unambiguously identify blood-borne pathogens that cause Sepsis, including bacteria and yeast species, as well as the identification of biothreat agents.

The aim of this project is to develop and provide Good Manufacturing Practice, Good Laboratory Practice and ISO13485 certifiable primer manufacturing capability for Microbio and the wider Australian ecosystem. Microbio will be able to supply high-quality manufactured primers for its own products as well as supply Australian laboratories with microbial DNA-free, ultra-pure and high-quality primers. Microbio is creating manufacturing capability not currently available in Australia. This capability will then enable sovereign product manufacture of the entire InfectID product suite.